Impact ledger
Codiak BioSciences, Inc. (CDNA): the developments shaping its investment case
Follow the evidence affecting Codiak BioSciences, Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Codiak BioSciences, Inc. · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-20 · 6 reports
Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pact
Channel: Sector sentiment, potential for similar partnerships, competitive dynamics.
watch· 1-3m
Event impact log
6 events mapped to CDNA since 2026-09-19. Evidence through 2026-09-20.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-20 | Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pact | Sector sentiment, potential for similar partnerships, competitive dynamics. | watch | 1-3m | 0.20 |
| 2026-09-19 | Twist Bioscience partners with Eli Lilly on TuneLab AI discovery | Increased competitive pressure in synthetic biology and antibody discovery services, potential for market share shifts. | watch | 1-3m | 0.30 |
| 2026-09-19 | Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discovery | Indirect sector sentiment and potential for future similar collaborations. | watch | 1-3m | 0.20 |
| 2026-09-19 | Twist Bioscience Partners with Eli Lilly on AI Drug Discovery Platform | Increased competitive pressure in the AI-driven drug discovery and synthetic biology services market. Potential for other major pharma companies to seek similar partnerships. | watch | 1-3m | 0.30 |
| 2026-09-19 | Twist Bioscience Partners with Eli Lilly on AI-Powered TuneLab Platform | Increased investor attention on companies leveraging AI/computational biology in life sciences, potential for similar partnerships. | watch | 3-12m | 0.30 |
| 2026-09-19 | Twist Bioscience Rallies 31% on Eli Lilly AI Drug Discovery Collaboration | Increased investor focus on AI-driven drug discovery platforms and related service providers, potential for sector re-rating. | watch | 3-12m | 0.20 |
Continue this research
Build your Codiak BioSciences, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the CDNA entity page →